Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Net Margin (2016 - 2025)

Altimmune (ALT) has disclosed Net Margin for 16 consecutive years, with 380280.0% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 7662000.0% to 380280.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 420165.0%, a 22104962.0% decrease, with the full-year FY2024 number at 475535.0%, down 45477279.0% from a year prior.
  • Net Margin was 380280.0% for Q3 2025 at Altimmune, up from 442920.0% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 164.27% in Q4 2021 to a low of 1178300.0% in Q3 2022.
  • A 5-year average of 273172.36% and a median of 251650.0% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -115709114bps in 2022, then soared 117258978bps in 2023.
  • Altimmune's Net Margin stood at 164.27% in 2021, then plummeted by -50613bps to 83307.69% in 2022, then dropped by -3bps to 85570.27% in 2023, then crashed by -445bps to 465960.0% in 2024, then increased by 18bps to 380280.0% in 2025.
  • Per Business Quant, the three most recent readings for ALT's Net Margin are 380280.0% (Q3 2025), 442920.0% (Q2 2025), and 391500.0% (Q1 2025).